Anticancer biology of Azadirachta indica L (neem): A mini review

• Published in: Cancer biology & therapy Vol. 12; no. 6; pp. 467 - 476
• Main Authors: Paul, Rajkumar, Prasad, Murari, Sah, Nand K.
• Format: Journal Article
• Language: English
• Published: United States Taylor & Francis 15-09-2011
• Subjects: Animals; Anticarcinogenic Agents - pharmacology; Anticarcinogenic Agents - therapeutic use; Antimutagenic Agents - pharmacology; Antimutagenic Agents - therapeutic use; Antineoplastic Agents, Phytogenic - pharmacology; Antineoplastic Agents, Phytogenic - therapeutic use; Azadirachta - chemistry; Binding; Biology; Bioscience; Calcium; Cancer; Cell; Clinical Trials as Topic; Cycle; Flowers - chemistry; Fruit - chemistry; Humans; Landes; Neoplasms - drug therapy; Neoplasms - prevention & control; Organogenesis; Plant Extracts - pharmacology; Plant Extracts - therapeutic use; Proteins; Seeds - chemistry
• ISSN: 1538-4047; 1555-8576
• DOI: 10.4161/cbt.12.6.16850

Neem (Azadirachta indica), a member of the Meliaceae family, is a fast growing tropical evergreen tree with a highly branched and stout, solid stem. Because of its tremendous therapeutic, domestic, agricultural and ethnomedicinal significance, and its proximity with human culture and civilization, neem has been called "the wonder tree" and "nature's drug store." All parts of this tree, particularly the leaves, bark, seed-oil and their purified products are widely used for treatment of cancer. Over 60 different types of biochemicals including terpenoids and steroids have been purified from this plant. Pre-clinical research work done during the last decade has fine-tuned our understanding of the anticancer properties of the crude and purified products from this plant. The anticancer properties of the plant have been studied largely in terms of its preventive, protective, tumor-suppressive, immunomodulatory and apoptotic effects against various types of cancer and their molecular mechanisms. This review aims at scanning scattered literature on "the anticancer biology of A. indica," related toxicity problems and future perspectives. The cogent data on the anticancer biology of products from A. indica deserve multi-institutional clinical trials as early as possible. The prospects of relatively cheaper cancer drugs could then be brighter, particularly for the under-privileged cancer patients of the world.